35.00 -2.00 (-5.41%)
After hours: 7:53PM EST
Previous Close | 37.47 |
Open | 37.18 |
Bid | 35.53 x 800 |
Ask | 36.84 x 800 |
Day's Range | 35.77 - 37.43 |
52 Week Range | 33.59 - 71.45 |
Volume | 449,273 |
Avg. Volume | 548,321 |
Market Cap | 1.646B |
Beta (5Y Monthly) | 1.23 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.75 |
Earnings Date | Oct 27, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 68.67 |
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Uniqure said Monday an independent panel recommended it continue enrolling patients in a study of its Huntington's disease gene therapy. In response, QURE stock popped on the news.
Shares of UniQure gained 7.2% in trading on Monday after the company said an independent data safety monitoring board said there were no safety concerns in a Phase 2/3 clinical trial for its experimental Huntington's disease treatment. The board has reviewed six months of safety data for the first two patients enrolled in the randomized, double-blind study. UniQure said it expects to enroll six more patients who have been diagnosed with the rare neurodegenerative disease by mid-2021. The investigational gene therapy is called AMT-130. "While early, we remain bullish about uniQure's [Huntington's disease] gene therapy and continue to believe the program is nearly all upside from current levels," Raymond James analyst Danielle Brill wrote in a note to investors. Uniqure's stock is down 35.9% for the past year, while the broader S&P 500 has gained 16.5%.